17,261 trials
Solid Tumor · Colorectal Cancer
Primary: Percentage of Participants With Dose Limiting Toxicities (DLT) — 16.7; 0.0; 0.0; 14.3 percentage of participants
Solid Tumors
Primary: Objective Response Rate (ORR) — 20.0; 30.0; 17.6; 0 percentage of participants
Cancer of the Pancreas
Primary: Change in Serum Adiponectin Level — 34.47; 29.77 μg/ml
Asthma · Rhinovirus · Picornaviridae Infections
Primary: Total Lower Respiratory Symptom Score — 21; 18 score on a scale — p=0.78
Head and Neck Cancer
Primary: Number of Participants With Progression-free Survival — 17 Participants
Breast Cancer
Primary: Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone — 8.41; 6.77 Months
Allergic Rhinitis Due to Tree Pollen · Allergic Conjunctivitis · Allergic Rhinoconjunctivitis
Primary: Average Daily Total Combined Score (TCS) — 10.1; 13.0 units on a scale — p=0.004
Advanced Malignancies · Metastatic Cancer
Primary: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) and as Per the Severity — 4; 4; 4; 3 Participants
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Relapse Incidence — 18 Participants
Chronic Viral Hepatitis B With Delta-agent
Primary: Percentage of Patients With Negative HDV RNA by PCR — 0; 53.3; 26.7; 6.7 Percentage of participants — p=0.0022
Myelodysplastic Syndrome · Acute Myeloid Leukemia · Myeloproliferative Neoplasm
Primary: Phase 1b: Maximum Tolerated Dose (MTD) — 4500 mg/day
Chronic Plaque-type Psoriasis
Primary: Proportion of Subjects Whose Plaque Achieves "Clear" or "Almost Clear" Status (TCS = 0-2) — 12; 8 Participants — p=0.1715
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019
Infant,Premature
Primary: Right Ventricular Energetic Efficiency Pre and Post Metoprolol — 15.5; 12.7 µJ/ml — p=0.004
Pancreatic Adenocarcinoma
Primary: Number of Participants With Relapse-free Survival — 3; 2 Participants